Sodival CR199.8 mg+87 mg

Sodival CR is an anticonvulsant (antiepileptic) and mood-stabilizing medicine. Its evidence-based uses are classified below.

Established / approved uses

• Epilepsy: Monotherapy or adjunctive therapy for simple and complex absence seizures, and as adjunctive therapy in patients with multiple seizure types that include absence seizures. Also used as monotherapy or adjunct for generalized tonic-clonic seizures and complex partial (focal) seizures.
• Bipolar disorder: Treatment of acute manic or mixed episodes associated with bipolar disorder.
• Migraine prophylaxis: Prevention of migraine headaches in adults (not for use during an acute migraine attack).

Adjunct / combination therapy

In patients with multiple seizure types, Sodival CR is frequently combined with other antiepileptic drugs; dose adjustment of co-administered agents (e.g., lamotrigine) is often required — see Interactions.

Off-label uses (not FDA-approved, evidence variable)

Sodival CR is sometimes used off-label for maintenance treatment of bipolar disorder, for status epilepticus (specific IV valproate formulations), for neuropathic pain, and for agitation in dementia; these uses are not established indications and should only be undertaken under specialist supervision.

Sodium Valproate + Valproic Acid is a combination (dual-component) anticonvulsant preparation containing sodium valproate and valproic acid in a fixed proportion, which together deliver the pharmacologically active valproate moiety. It is available as delayed-release/enteric-coated tablets in strengths such as 200 mg, 300 mg and 500 mg, and as an oral liquid, with strength expressed as total valproate content.

Sodival CR is a widely used, well-established anticonvulsant that has been in clinical use for decades for the treatment of various seizure disorders, bipolar disorder, and migraine prevention. It combines sodium valproate and valproic acid, both of which are converted to the valproate ion in the gastrointestinal tract, providing predictable and stable blood levels.

Sodival CR carries important safety considerations, including a well-established risk of liver toxicity, pancreatitis, and significant harm to a developing fetus if used during pregnancy. Treatment should always be initiated and monitored by a physician experienced in managing epilepsy or bipolar disorder.

Sodival CR belongs to the anticonvulsant (antiepileptic drug) class and is also classified as a mood stabilizer used in psychiatry.

The precise mechanism of action of Sodium Valproate + Valproic Acid in epilepsy, bipolar disorder and migraine is not completely understood. Proposed mechanisms include:

• Increasing brain levels of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter, by inhibiting GABA transaminase and enhancing GABA synthesis.
• Blocking voltage-gated sodium channels, reducing sustained high-frequency repetitive neuronal firing.
• Modulating T-type calcium channels, which is thought to contribute to its efficacy against absence seizures.

Both sodium valproate and valproic acid dissociate to the active valproate ion after administration; therefore the two components act pharmacologically as a single moiety. Valproate is well absorbed orally, is highly (80–90%) plasma-protein bound, and is metabolized mainly in the liver via glucuronidation and beta-oxidation, with a small but clinically important oxidative pathway responsible for a hepatotoxic metabolite.

Sodival CR is taken by mouth, generally with food to minimize stomach upset. Delayed-release (enteric-coated) tablets should be swallowed whole and not crushed, chewed, or split, as this can affect the controlled release of the medicine. Doses are usually divided across the day (2–3 times daily) unless an extended-release formulation intended for once-daily use is prescribed. Do not discontinue Sodival CR suddenly without consulting your physician.

Sodival CR has several clinically important drug interactions:

• Lamotrigine: Sodival CR significantly inhibits lamotrigine metabolism, markedly increasing lamotrigine blood levels and the risk of serious skin reactions (including Stevens-Johnson syndrome); lamotrigine dose must be reduced when co-administered.
• Carbapenem antibiotics (e.g., meropenem, imipenem, ertapenem): Co-administration can cause a rapid, significant drop in valproate blood levels, which may precipitate breakthrough seizures; this combination should generally be avoided, and if unavoidable, seizure control and valproate levels should be closely monitored.
• Other antiepileptic drugs (e.g., phenytoin, phenobarbital, carbamazepine): Complex, variable interactions occur, generally involving altered clearance of one or both drugs; combined use requires close monitoring and dose adjustment.
• Aspirin and other highly protein-bound drugs: May displace valproate from plasma protein-binding sites, increasing free (active) valproate levels and toxicity risk.
• Warfarin and other anticoagulants: Sodival CR may potentiate anticoagulant effect by displacing warfarin from protein-binding sites; monitor coagulation parameters more closely.
• CNS depressants (alcohol, benzodiazepines, opioids): Additive sedation and CNS depression may occur.

Common and serious side effects associated with Sodival CR include:

Common

• Nausea, vomiting, indigestion, abdominal pain, diarrhea
• Tremor
• Weight gain, increased appetite
• Hair loss (usually reversible)
• Drowsiness, dizziness, headache
• Menstrual irregularities

Less common but serious (see Precautions and Warnings for full detail)

• Hepatotoxicity — can be severe or fatal, particularly in young children; requires liver function monitoring.
• Pancreatitis — can be life-threatening and may occur at any point during treatment.
• Thrombocytopenia and other blood dyscrasias (bruising, bleeding).
• Hyperammonemia — can cause lethargy and confusion, and notably can occur even when liver function tests are normal.

Sodival CR carries a well-established, serious risk to a developing fetus and should be used in pregnancy only if clearly needed, when no other effective alternative exists, and after specialist consultation.

Sodival CR is one of the most strongly teratogenic anticonvulsants: exposure during pregnancy is associated with a significantly increased risk of neural tube defects (e.g., spina bifida) and other major congenital malformations, as well as documented reductions in cognitive scores (IQ) and increased risk of neurodevelopmental disorders, including autism spectrum disorder, in children exposed in utero. Because of this well-established teratogenic and neurodevelopmental risk, Sodival CR is specifically contraindicated for migraine prophylaxis in pregnant women, and its use for epilepsy or bipolar disorder during pregnancy should be reserved for situations where the potential benefit clearly outweighs the potential risk to the fetus and no safer alternative is suitable. Women of childbearing potential should use effective contraception while taking Sodival CR, and folic acid supplementation is recommended before and during pregnancy if use cannot be avoided. Pregnant women taking Sodival CR should be enrolled in an appropriate pregnancy registry where available and monitored closely by a specialist.

Lactation: Valproate is present in breast milk at relatively low concentrations. Available data have not shown obvious adverse effects in most breastfed infants, and breastfeeding may be considered while using Sodival CR, but the infant should be monitored for signs of liver problems, unusual bruising/bleeding, or sedation; discuss the benefits and risks with your physician.

Hepatotoxicity (potentially fatal)

Sodival CR can cause severe, sometimes fatal, liver failure, particularly during the first six months of treatment. Children under 2 years of age, patients on multiple anticonvulsants, patients with inherited metabolic or mitochondrial disorders (including POLG mutations), and patients with severe seizure disorders accompanied by intellectual disability are at highest risk. Liver function tests should be performed before starting treatment and periodically thereafter, especially during the first six months. Symptoms such as loss of seizure control, malaise, weakness, lethargy, facial edema, anorexia, vomiting, and jaundice should prompt immediate medical evaluation and possible discontinuation.

Pancreatitis (potentially life-threatening)

Cases of life-threatening pancreatitis have been reported in both children and adults, and can occur shortly after starting therapy or after years of use. Patients should be advised to seek prompt medical attention for abdominal pain, nausea, vomiting, or anorexia, and Sodival CR should generally be discontinued if pancreatitis is diagnosed.

Teratogenicity and fetal risk

See Pregnancy and Lactation for full detail on the well-established, serious risk of major congenital malformations and neurodevelopmental impairment with in-utero exposure.

Hyperammonemia and encephalopathy

Sodival CR can cause hyperammonemic encephalopathy, which may present with lethargy, vomiting, and altered consciousness, and can occur even with normal liver function tests; it is more likely in patients with urea cycle disorders (a contraindication) or when combined with certain other antiepileptics (e.g., topiramate).

Thrombocytopenia and bleeding risk

Sodival CR can cause dose-related thrombocytopenia and platelet dysfunction; periodic blood counts and coagulation assessment are advised, particularly before surgery.

Suicidal behavior and ideation

As with other antiepileptic drugs, Sodival CR may increase the risk of suicidal thoughts or behavior. Patients and caregivers should be alert for mood changes, worsening depression, or unusual behavior changes and report these promptly.

Somnolence in the elderly

Elderly patients may be more sensitive to the sedative effects of Sodival CR; dose should be increased more slowly, with attention to fluid/nutritional intake, and monitored for somnolence and reduced alertness.

Driving and operating machinery

Sodival CR can cause drowsiness or dizziness; patients should avoid driving or operating heavy machinery until they know how it affects them.

Overdose with Sodival CR is a medical emergency. Symptoms can include deep sleepiness progressing to coma, muscle weakness, low blood pressure, cardiovascular instability, and metabolic disturbances. If an overdose is suspected, seek immediate emergency medical attention or contact a poison control center right away; do not attempt to treat an overdose at home. Hospital management may include supportive care and, in significant overdose, specialized treatments determined by medical staff.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pregnancy

See Pregnancy and Lactation for detailed, important safety information — Sodival CR carries a well-established serious risk to a developing fetus.

Elderly

Use a lower starting dose and slower titration; elderly patients are more susceptible to somnolence and reduced fluid/food intake — see Precautions and Warnings.

Renal impairment

Dose adjustment may be required as a greater proportion of drug is unbound; monitor clinical response and, where available, free valproate levels.

Hepatic impairment

Sodival CR is contraindicated in patients with significant hepatic disease or dysfunction — see Contraindications.

Pediatric patients

Sodival CR is approved for use in children for certain seizure types; however, it carries a substantially higher risk of fatal hepatotoxicity in children under 2 years of age, especially those with metabolic or mitochondrial disorders, or on multiple anticonvulsants — see Contraindications and Precautions and Warnings. Safety and efficacy in bipolar disorder and migraine prophylaxis have not been established in pediatric patients.

Duration of treatment with Sodival CR is individualized by the treating physician based on indication, response, and tolerability. In epilepsy, treatment is often long-term (sometimes lifelong), with periodic reassessment of the need for continued therapy. In acute mania, treatment continues through the acute episode and is often continued for maintenance under specialist guidance. For migraine prophylaxis, response is usually assessed after 2–3 months, with continued need reviewed periodically. Sodival CR should never be stopped abruptly without medical advice, since sudden discontinuation can precipitate seizures or status epilepticus.

Anticonvulsants (Antiepileptic drugs); Mood stabilizers

Sodium Valproate + Valproic Acid is believed to act primarily by increasing brain concentrations of the inhibitory neurotransmitter GABA and by blocking voltage-gated sodium channels, which together dampen excessive and repetitive neuronal firing. It may also modulate T-type calcium channels, contributing to control of absence seizures. Both sodium valproate and valproic acid convert to the same active valproate ion, giving the combination a unified pharmacologic action.

D (X specifically for the migraine-prophylaxis indication)

Sodival CR is approved for use in pediatric patients for certain seizure types, including absence seizures and, as adjunctive therapy, other seizure types, under close specialist supervision. Dosing is weight-based and individualized. Children under 2 years of age are at markedly increased risk of fatal hepatotoxicity, especially those with inherited metabolic or mitochondrial disorders (including POLG-related disorders, which are a contraindication in this age group) or those receiving multiple anticonvulsants — see Contraindications and Precautions and Warnings. Safety and efficacy of Sodival CR for bipolar disorder and migraine prophylaxis have not been established in children, and it is not recommended for these indications in the pediatric population.